Literature DB >> 970185

Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation.

R Deberdt.   

Abstract

Pipamperone solution or tablets were prescribed for four weeks to 188 patients (3-100 years) with behavior disorders. Fifty of these (group A) were mental retardates, the remaining 138 (group B) had a normal I.Q. Their doses were gradually increased until optimal effect was reached. Nearly all 17 items of a behaviour rating scale had improved very significantly by the end of the fourth week, while in 82% of the patients of group A and 76% of group B results were rated good to very good. Also, pipamperone proved to be far superior to previous psychotropic drugs in patients who had been treated before.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 970185

Source DB:  PubMed          Journal:  Acta Psychiatr Belg        ISSN: 0300-8967


  4 in total

1.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 2.  Survey on the pharmacodynamics of the new antipsychotic risperidone.

Authors:  A A Megens; F H Awouters; A Schotte; T F Meert; C Dugovic; C J Niemegeers; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

3.  Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

Authors:  J E Leysen; P M Janssen; A Schotte; W H Luyten; A A Megens
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.

Authors:  F Mesotten; E Suy; M Pietquin; P Burton; S Heylen; Y Gelders
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.